The Role of Platelet-rich Plasma in Osteoarthritis of Knee-joint

Sheikh Forhad^1, , Erfanul Huq Siddiqui¹, Md. Shamsul Alam², Anjumun Ara³ and Jannat Sultana⁴

¹Department of Orthopaedic Surgery, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh

²Department of Orthopedics, Gazaria Upazila Health Complex, Munshigonj, Bangladesh

³Department of Obstetrics and Gynaecology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh

⁴Department Paediatric Medicine, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh

Cite this paper

Sheikh Forhad, Erfanul Huq Siddiqui, Md. Shamsul Alam, Anjumun Ara and Jannat Sultana. The Role of Platelet-rich Plasma in Osteoarthritis of Knee-joint. American Journal of Medical and Biological Research. 2021; 9(1):1-4. doi: 10.12691/AJMBR-9-1-1

Abstract

Background: Osteoarthritis is one of the leading causes of disability. Platelet-rich plasma (PRP) is known as autologous conditioned plasma is a concentrate of platelet-rich plasma protein derived from whole blood, centrifuged to remove red blood cells. Now it is used in treating OA. We have very few data regarding this issue. The aim of this study was to assess the role of platelet-rich plasma in osteoarthritis of knee-joint. Materials and methods: This was a prospective observational study which was conducted at the Department of Orthopaedics & Traumatology, Bangabandhu Sheikh Mujib Medical University (BSMMU) Dhaka, Bangladesh during the period from January 2018 to December 2018. In total 89 patients, diagnosed with grade I and II arthritis were included in this study as the study population. To all the participants three PRP injections were injected in the knees at 4-week interval. Patients were followed up and were assessed for pain and physical activity associated with arthritis using the Western Ontario and McMaster University Arthritis Index (WOMAC) score at the time of induction in the study and at 6 months interval. Results: The mean (±SD) WOMAC score of the participants was 82.94 (±5.12) at the baseline whereas it was found 37.87 (±4.73) at the follow up period after 6 months. After 6 months the mean (±SD) WOMAC score of male participants was found 36.93 (±5.71) and it was found 38.87 (±5.39) among female participants. This difference was statistically significant (P=0.021). Besides this, after 6 months the mean (±SD) WOMAC score of Kellgren–Lawrence grade-1 participants was 37.68 (±5.44) and it was found 40.13 (±5.01) among Kellgren–Lawrence grade-2 participants. This difference was statistically significant (P=0.002). Moreover, after 6 months the mean (±SD) WOMAC score of participants with ≤2 years duration of symptoms was 37.95 (±5.37) and it was found 41.66 (±4.28) among participants with >2 years duration of symptoms. This difference was extremely statistically significant. Conclusions: The proper sequential use of PRP injection for the treatment of osteoarthritis of knee-joint proved to be effective in our study. We recommend its wide use in the treatment of osteoarthritis of knee-joint.

Keywords

osteoarthritis, Platelet-rich plasma (PRP), knee joint, orthopedics

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Wright Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin N Am. 2013; 39(1): 1-19.
[2]	Duymus TM, Mutlu S, Dernek B, Komur B, Aydogmus S, Kesiktas FN. Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options. Knee Surg Sports Traumatol Arthrosc. 2017; 25(2): 485-92.
[3]	Raeissadat SA, Rayegani SM, Babaee M, et al. The effect of platelet-rich plasma on pain, function, and quality of life of patients with knee osteoarthritis. Pain Res Treat 2013; 2013: 165967.
[4]	Litwic A, Edwards MH, Dennison EM, et al. Epidemiology and burden of osteoarthritis. Br Med Bull 2013; 105: 185-199.
[5]	Deshpande BR, Katz JN, Solomon DH, et al. Number of persons with symptomatic knee osteoarthritis in the US: impact of race and ethnicity, age, sex and obesity. Arthritis Care Res (Hoboken) 2016; 68(12): 1743-1750.
[6]	Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7(1): 33-42.
[7]	Martel-Pelletier J, Boileau C, Pelletier JP, et al. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol 2008; 22(2): 351-384.
[8]	Michael JW, Schlu¨ter-Brust KU, and Eysel P. The epidemiol- ogy, etiology, diagnosis, and treatment of osteoarthritis of the knee. Dtsch Arztebl Int 2010; 107(9): 152-162.
[9]	Smyth NA, Haleem AM, Ross KA, et al. Platelet-rich plasma may improve osteochondral donor site healing in a rabbit model. Cartilage 2016; 7(1): 104-111.
[10]	Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet- rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 2013; 41(2): 356-64.
[11]	Lee KS, editor. Platelet-rich plasma injection. Seminars in musculoskeletal radiology. New York: Thieme Medical Publishers; 2013.
[12]	Lana JFSD, Weglein A, Sampson SE, Vicente EF, Huber SC, Souza CV, et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. J Stem Cells Regen Med. 2016; 12(2): 69-78.
[13]	Spakova T, Rosocha J, Lacko M, Harvanova D, Gharaibeh A. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil. 2012; 91(5): 411-7.
[14]	Andia I, Sa´nchez M, and Maffulli N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol Ther 2012; 12(1): 7-22.
[15]	Khoshbin A, Leroux T, Wasserstein D, et al. The efficacy of platelet-rich plasma in the treatment of symptomatic knee osteoarthritis: a systematic review with quantitative synth- esis. Arthroscopy 2013; 29(12): 2037-2048.
[16]	Filardo G1, Kon E, Buda R, et al. Platelet-rich plasma intra- articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2011; 19(4): 528-535.
[17]	Kon E, Buda R, Filardo G, et al. Platelet-rich plasma: intra- articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 2010; 18(4): 472-479.
[18]	Jang SJ, Kim JD, and Cha SS. Platelet-rich plasma (PRP) injections as an effective treatment for early osteoarthritis. Eur J Orthop Surg Traumatol 2013; 23(5): 573-580.
[19]	Patel S, Dhillon MS, Aggarwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013; 41(2): 356-364.